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Optimize Clinical Research in the Era of Molecularly Diverse Oncology
Howard (Jack) West, MD,* and D. Ross Camidge, MD, PhD†
Our conceptualization of oncology is undergoing a revolutionary transition based onadvances in the molecular categorization of cancer. This recognition of the impor-
tance of molecular diversity has led to clear advances not just in the understanding of, but
in the targeted treatment for, specific and increasingly narrow subtypes of many cancers.
Using lung cancer as an example, epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors or crizotinib have been clearly demonstrated to produce response rates in
the 60 to 75% range and prolonged progression-free survival in the range of 9 to 13
months when given to patients with an activating EGFR mutation1–4 or anaplastic
lymphoma kinase (ALK) translocation,5 respectively. Although these results represent
treatment breakthroughs for subgroups of patients, the implications for clinical research
focusing on cancer patient subpopulations are only just becoming apparent.
The frequency of EGFR mutations varies geographically but is present in only
approximately 10 to 15% of the Caucasian lung cancer population. ALK gene rearrange-
ments are present in only approximately 4% of cases from series containing predomi-
nantly adenocarcinoma of the lung.6,7 Recently, the US-based Lung Cancer Mutation
Consortium tested for 10 different potentially “druggable” molecular abnormalities in
1000 patients with advanced lung adenocarcinoma. Among the data available from the
first 516 fully analyzed cases, 54% had an identified abnormality, with 97% of these being
mutually exclusive.8 After KRAS mutations (22%), EGFR mutations, and ALK gene
rearrangements were accounted for, the other seven abnormalities together represented
less than 8% of the total non-small cell lung cancer population.
As most of the agents with the potential to act on a specific molecularly defined
subset are only available within clinical trials, how do we conduct a trial when the
requisite patients are geographically diluted, and even a large center may only see one or
two cases of a particular molecular subtype in a given year? Conversely, if you are a
patient and learn that you fall within a specific molecularly defined subgroup, how do you
get access to the best information and treatment on your disease when even the most
common cancers are now fragmenting into rare subdiseases? The greater magnitude of
potential benefit with more carefully selected matching of treatment to patient subpopu-
lations now raises the value for patients to pursue them across significant distances. The
success of such a model is predicated on patients and caregivers having access to
high-quality, timely information about emerging therapies, without misrepresenting the
potential clinical benefits for trial participants. Essentially, this means good communica-
tion between knowledgeable physicians and an engaged patient community. These
opportunities have become increasingly available through channels such as American
Society of Clinical Oncology’s patient website (www.cancer.net) and a growing collection
of other high-quality educational resources.
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One of us (H.J.W.) leads a free social media-based
community for patients along with their caregivers called the
Global Resource for Advancing Cancer Education (GRACE)
(www.cancergrace.org), which provides an ongoing stream
of medically curated content as well as an interactive question
and answer forum moderated by a rotating panel of expert
cancer clinicians. Although covering several different can-
cers, to date it has mostly focused on lung cancer. In February
2010, GRACE hosted a podcast by one of us (D.R.C.) on the
emerging ALK story in non-small cell lung cancer,9 explain-
ing the details and location of the ongoing crizotinib trials and
the requirements for proven ALK positivity before study
entry. The podcast has since been streamed or downloaded
more than 1300 times, primarily by patients and caregivers.
Until the last crizotinib lung cancer trials closed to accrual in
2011, patients had traveled to the University of Colorado’s
lung cancer program from 15 different US states and one
non-US country (South Africa) to pursue the opportunity to
participate in clinical trials with this agent (Figure 1). Of note,
the University of Colorado has traditionally conducted very
little direct-to-patient advertising locally and none either
nationally or internationally. Therefore, GRACE and other
online lung cancer patient support communities, along with
news media coverage, are likely to represent the dominant
sources informing patients living outside the state of the
study’s presence at the University of Colorado.
Molecular drivers of cancer and their potential to derive
benefit from specific therapies are likely to cross traditional
tumor type-specific boundaries—e.g., ALK gene rearrange-
ments and responses to crizotinib have also been reported in
patients with inflammatory myofibroblastic tumors, a rare
sarcoma.10 Reorganizing information resources along molec-
ular lines in response to new data may prove to be far easier
within online communities than it will be within the estab-
lished tumor type-specific practices of community and aca-
demic oncologists.
How can we address the logistical challenges of con-
ducting clinical trials among geographically dispersed and
molecularly diverse populations, beyond the initial optimiza-
tion of information and mutual support for potential partici-
pants in online communities? Dramatically streamlining the
opening of clinical trials could be one solution—essentially
adopting an “off-the-peg” trials approach so that having
found a patient with a molecular abnormality, access to the
drug in a trial can be brought quickly and efficiently to the
patient at their nearest treating facility. Although this sounds
simple, the challenges associated with such an approach
would be considerable. Clinical trials are very carefully
regulated, and clinical trial sites and investigators are care-
fully monitored. Although undoubtedly inefficiencies in the
process exist and could be improved upon, bringing the trial
to the patient in a timeframe that is unlikely to compromize
their clinical care, but which preserves Good Clinical Practice
and remains in accordance with the Declaration of Helsinki,
would be hard to achieve. Alternatively, for patients who
already know or suspect their molecular abnormality but
would need to travel a significant distance for experimental
therapies, several developments would significantly facilitate
clinical research in this setting, beyond simply including
some travel and overnight accommodation reimbursement
within study budgets. At present, patients usually travel to
involved sites to offer their consent and then return to be
screened for the trial, necessitating several different trips
before treatment starts. Phone consultation followed by the
exchange of consent forms via fax or e-mail before a first visit
is eminently feasible but currently not reimbursed by most
FIGURE 1. Origin of lung cancer patients (green circles) who participated in crizotinib clinical trials at the University of Colo-
rado (red circle) (62% from Colorado, 36% from other US states, 2% international [Johannesburg, South Africa; not shown];
n  39).
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insurers or in most study budgets. Moreover, most scans,
routine laboratory tests, and electrocardiograms are con-
ducted on site during a clinical trial, but using local facilities
with their associated normal ranges for laboratory values
should also be feasible for some “visits,” and imaging dis-
tantly and relaying to the treating center could also be
possible if the software for viewing images can be better
standardized across centers. Instead of traveling on days
without treatment, toxicity checks could be conducted over
the phone or via Health Insurance Portability and Account-
ability Act-compliant, encrypted video links, and local prac-
titioners could conduct standardized physical examinations if
these and the oversight and coordination time involved were
reimbursable.
If the molecular abnormality is not yet proven within an
individual patient’s tumor, additional challenges will arise.
Pharmaceutical companies pursuing molecularly specific li-
censes for their drug will usually file in conjunction with data
to support a specific companion diagnostic. To ensure stan-
dardization, such testing may need to be conducted within a
central testing facility. Although in the initial crizotinib trials
many patients were required to travel to study sites simply to
sign a prescreening consent form that allowed their tumor to
then be sent for central testing, there is no reason to follow
this precedent. Again, phone consent for prescreening and
addressing shipping costs and coordination costs to facilitate
this process without the patient having to travel before re-
ceiving a positive screening result are all relatively easily
achievable changes to facilitate clinical research across dis-
parate populations. When community testing for a marker is
available, additional opportunities exist. In this scenario,
sponsors could permit study entry based on locally developed
tests and then follow this with retrospective central confir-
mation, recognizing but accepting that the number of evalu-
able centrally positive cases will inevitably be smaller than
the total number enrolled on the study.
Even with such improvements, a sponsor is still
charged with the decision of where to open such molecularly
specific trials. As described above, “off-the-peg” models
designed to bring the trial to the patient in real-time are likely
to be problematic. Instead, sites currently, and for the fore-
seeable future, are chosen well in advance of the first eligible
patient being identified. Realistically, it may be most eco-
nomically feasible to pursue a new model that involves
opening molecularly specific trials at a few geographically
dispersed centers and requiring motivated patients to travel to
an accessible center, rather than the alternative of opening the
same trial in large numbers of low accruing sites. The striking
similarity of Figure 1 to an airline’s network of connections
utilizing key “hubs” located across the country raises the
question of whether a similar model utilizing “trial hubs”
should actively be pursued for clinical research involving rare
cancers/molecular subgroups.
The last decade has ushered in a sea change in the
practice of oncology, largely as a result of new molecularly
defined subgroups being identified within what were previ-
ously perceived as monolithic broad cancer populations. This
transition has led to remarkable benefits when narrower
subsets of patients have been the optimal beneficiaries of a
novel, molecularly guided therapy, but it has also introduced
practical challenges in which the low geographic density of
these newly defined subgroups have made it increasingly
difficult to follow traditional models for clinical research. The
oncology and pharmaceutical communities now have the
option of adapting to this new era in a number of different
ways. Online patient communities can now be leveraged to
partner with clinical researchers in getting patients appropri-
ately informed and motivated. Clinical trial costs, conduct,
and site locations can all be modified to overcome many of
the geographic limitations. The proposed changes may be
new, but they are not hard to achieve. In this we are fortunate,
for only by embracing the practical reality of cancer’s in-
creasingly revealed diversity will we be able to capitalize on
and accelerate the pace of molecularly guided clinical re-
search in the future.
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